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Background: The histological grade is the gold standard for the evaluation of prognosis of astrocytic tumors.
Nevertheless, morphologic criteria are not always accurate prognostic indicators.
Aim: The research investigates the expression of MIB-1 and DJ-1 in different grades of astrocytomas and evaluates
the possible prognostic role of DJ-1 in these tumors in relation to other prognostic parameters including the MIB-1
labeling index.
Materials and methods: Immunohistochemical expression of MIB-1 and DJ-1 was evaluated in 111 samples of
astrocytic tumors comprising 28 diffuse astrocytomas, 38 anaplastic astrocytomas and 45 glioblastomas. The
univariate survival analysis was done using the Kaplan-Meier method and the multivariate survival analysis was
done using Cox proportional hazard model.
Results: The statistical analysis revealed a significant correlation between each of DJ-1 and MIB-1 and the
histological grade of astrocytomas. The univariate analysis showed that high grade, high DJ-1 score and MIB-1
labeling index ≥ 10.1 were associated with poor survival. Multivariate analysis for all the studied astrocytomas
proved the independent prognostic significance of the histological grade and DJ-1 score. Meanwhile, the
multivariate analysis for each grade emphasized that DJ-1 was the only independent prognostic indicator in
high-grade astrocytomas.
Conclusion: This study emphasized the effectiveness of high DJ-1 expression in predicting poor survival of
astrocytoma patients, when compared to MIB-1. DJ-1 could be particularly important in cases with discrepancies
between the morphologic criteria and clinical parameters.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.
eu/vs/1070116023943146
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Tumor grading is one of the most significant predictors
of the clinical outcome. Astrocytomas, the most com-
mon primary intracerebral tumors are not an exception
in this respect. The high-grade astrocytomas are usually
associated with poor prognosis. However, the histo-
logical differentiation may be confusing in some cases,
especially when small stereotactic guided needle biopsies
are available. Therefore studies have employed additional* Correspondence: rashashaban9000@yahoo.com
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distribution, and reproduction in any mediumdiagnostic and prognostic measures for predicting clin-
ical outcome and survival [1].
Many studies have focused on the proliferative activity
in astrocytomas especially ki-67/MIB-1 labeling index
(LI). MIB-1 antibody is an IgG1 class monoclonal anti-
body which recognizes a core antigen present in the nu-
clei of the cells in the G1, S, G2 and M phases of the
cell cycle, but is not expressed in the resting phase, G0
[2]. Importantly, the MIB-1 LI is not a component of the
WHO grading scheme for glial neoplasms [3]. However
many investigations have demonstrated a significant
positive correlation between MIB-1 indices & histo-
logical grade and have shown that higher MIB-1 LI is as-
sociated with shorter survival [4,5].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and antiapoptotic properties. The antioxidative role of
DJ-1 results from its participation in mitochondrial
stabilization upon exposure to an oxidative stress [6,7].
The antiapoptotic ability of DJ-1 is attributed to several
mechanisms: inhibition of phosphatase and tensin homo-
log (PTEN) mediated inhibition of the phoshoinositide
3-kinase (PI3K)/AKt antiapoptotic pathway. DJ-1 in-
teracts with and inhibits the function of death-
associated protein 6 (Daxx) which binds to apoptosis
signal-regulating kinase1 to promote apoptosis [8].
DJ-1 also induces Nrf2 stability, which in turn acti-
vates the transcription of antioxidant and detoxifica-
tion enzymes [6]. More recently DJ-1 has been shown
to have a direct role in inhibiting apoptosis by de-
creasing the expression of Bax and inhibits caspase
activation [9].
This strong antiapoptotic function of DJ-1 may have a
significant impact on neoplastic transformation and
tumor proliferation in humans, a possibility that is sup-
ported by DJ-1 expression in many cancers. DJ-1 has
been reported to be over expressed in lung, breast, pan-
creas, esophageal and urinary bladder cancers [10-12].
As regards the astrocytic tumors, DJ-1 expression may
be particularly important since it is prominently expressed
in reactive astrocytes in both acute and chronic forms of
human neurodegenerative diseases [13,14].
The important role of DJ-1 as an oncogene suggests
that it may be a possible prognostic indicator in patients
with astrocytomas.
This study investigates the possible role of DJ-1 in the
progression and prognosis of astrocytic tumors and em-
phasizes the relationship between DJ-1 and other im-
portant prognostic factors including the MIB-1 LI.
Materials and methods
A retrospective study included a total number of 111
formalin-fixed and paraffin embedded primary supratentorial
astrocytomas that were surgically resected (attempt of
debulking) at the neurosurgery department of Ain Shams
University Hospitals, Cairo, Egypt during the period from
January 2005 until January 2008. The clinical data were
obtained from the patients’ medical records and included
age, sex and postoperative survival data.
The patients in this study included 74 males (66.7%)
and 37 females (33.3%) with a mean age of 48.5 ± 10.8
(range: 12–71). The follow up period was the interval
from the date of initial diagnosis until the date of death,
or the completion of the research. During the follow up
period, 92 patients (82.9%) died of the disease, while 19
patients (17.1%) were still alive by the end of the study
with median survival 20m (range: 3m-68m). The study
was carried out with full local ethical approval. This
study gained the institutional review board approvalfrom Research Ethical Committee at Faculty of Medicine,
Ain Shams University.
Pathology slides from all resected tumor specimens
were reviewed by each author to confirm the diagnosis
of each grade of the studied astrocytoma cases using
the established criteria of the WHO classification of
the brain tumors [3]. The availability of sufficient suit-
able material for the immunohistochemical studies was
essential.
The astrocytoma cases were classified into 28 diffuse
astrocytomas (grade II), 38 anaplastic astrocytomas
(gradeIII) and 45 glioblastomas (GBMs) (grade IV). The
grading of necrosis in GBMs was based on the amount
observed in magnetic resonance imaging (MRI) scans.
The following grading system was applied: grade 0, no
necrosis; grade 1, amount of necrosis is < 25% of the
tumor volume; grade 2, amount of necrosis is between
25% and 50% of the tumor volume; grade 3, amount of
necrosis is > 50% of the tumor volume [15]. Grade 1 ne-
crosis, grade 2 necrosis and grade 3 necrosis were ob-
served in 42.2% (19/45), 40% (18/45) and 17.8% (8/45) of
the studied GBMs respectively.Immunohistochemistry
All 111 astrocytoma samples were subjected to immuno-
histochemical staining with MIB-1 and DJ-1 antibodies.
The paraffin embedded tissue sections were deparaffinized
in xylene and rehydrated through absolute alcohol.
Antigen retrieval in citrate buffer (pH9 Lab vision
cat#AP9003) was used after the sections were treated
in a microwave at 8w for 5–6 min, then at 3w for 10
min; the sections were then left to cool for 20 min.
Peroxidase and protein block were done. Following this,
slides were incubated overnight with each of the primary
antibodies at room temperature using MIB-1 antibody
(rabbit monoclonal antibody, 7 ml, Lot. No. 1210212B,
Cell marque, CA, USA) and DJ-1antibody (mouse mono-
clonal antibody, dil (1:20), Cat # 37–8800, Cell marquee,
CA, USA), followed by rinsing in PBS (pH7.6) This was
followed by the secondary biotin conjugated antibody
for 1 hour and finally the peroxidase conjugated
streptavidin for another hour. Diaminbenzidine tetrachlor-
ide (DAB) (freshly prepared) was added for 25 min, then
counterstained in Harris Hematoxylin, followed by dehy-
dration, clearing and mounting. Positive control for MIB-
1 antibody was breast carcinoma, while positive control
for DJ-1 was prostatic and kidney tissue. Negative controls
were done by excluding the primary antibody and its re-
placement with a non-immune antibody.Interpretation of immunohistochemical staining of MIB-1
The results of immunohistochemical staining were
assessed by each author and a consensus regarding
Abd El Atti et al. Diagnostic Pathology 2013, 8:126 Page 3 of 9
http://www.diagnosticpathology.org/content/8/1/126controversial cases was reached at a multiheaded
microscope.
MIB-1 imunostaining was evaluated in the fields of
maximal labeling. The MIB-1 LI was the number of
MIB-1 labeled tumor nuclei expressed as a percentage ofFigure 1 MIB-1 labeled nuclei in astrocytomas. a: In diffuse
astrocytoma (MIB-1x200). b: In anaplastic astrocytoma (MIB-1x200).
c: In glioblastoma (MIB-1x200).the total number of tumor nuclei counted. A total of at
least 1000 nuclei was counted in each case [1].Interpretation of immunohistochemical staining of DJ-1
The score of DJ-1 cytoplasmic immunoreactivity was
assigned based on the intensity of staining. The score
was ranging from 0 to 3 (i.e. 0 = negative, 1 = weak in-
tensity, 2 =moderate intensity, 3 = strong intensity) [10].Statistical analysis
Continuous variables are expressed as mean or median
and Standard Deviation. Categorical variables are
expressed as frequencies and percents. The ROC Curve
(receiver operating characteristic) was used to evaluate the
Sensitivity and specificity of MIB in prediction of mortality
among cases. ANOVA Test was used to assess the statis-
tical significance of the difference between more than two
study group mean. Chi square and Fisher’s exact test were
used to examine the relationship between Categorical var-
iables. Spearman’s correlation was used to assess the cor-
relation between grade and DJ. Survival rates were
estimated and graphed using the Kaplan-Meier method.
Log rank test was used to compare time-to-event variables
by levels of a factor variable. Cox Regression was used for
modeling the time to a specified event, taking into consid-
eration the values of other given variables. A significance
level of P < 0.05 was used in all tests. All statistical proce-
dures were carried out using SPSS version 15 for Win-
dows (SPSS Inc, Chicago, IL, USA).Figure 2 ROC curve to evaluate the sensitivity and specificity of
MIB in prediction of mortality.
Figure 3 Kaplan-Meier overall survival curves for tumors with
MIB-1 LI < 10.1 and MIB-1 LI ≥ 10.1.
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Immumohistochemical results
MIB-1 expression and its associations in the studied
astrocytoma cases
The mean MIB-1 LI of diffuse astrocytomas, anaplastic
astrocytomas and GBMs were (4.26 ± 2.43), (13.54 ±
2.82) and (26.43 ± 5.18) respectively. There was a signifi-
cant difference between the diffuse astrocytomas, the ana-
plastic astrocytomas and the GBMs as regard the mean
MIB-1 LI (F = 295.9, P = 0.0001). The Post hoc test (LSD)
revealed a significant difference in the mean MIB-1 LI be-
tween the diffuse and anaplastic astrocytomas (P = 0.001),
and the anaplastic astrocytomas and GBM cases (P = 0.001)
(Figure 1a, 1b and 1c).
The MIB-1 LI of 10.1 was considered to be a highly
significant prognostic cut off value, as MIB-1 LI ≥ 10.1Table 1 Relation between DJ-1 and clinicopathological variab
DJ-1 0 DJ-1 1
N Row % N Row %
Grade Grade II 8 28.6% 17 60.7%
Grade III 0 .0% 0 .0% 2
Grade IV 0 .0% 0 .0%
Sex Male 5 6.8% 13 17.6% 2
Female 3 8.1% 4 10.8%
Age group <50 years 6 10.9% 11 20.0% 1
≥50 years 2 3.6% 6 10.7% 1
MIB group <10.1 8 24.2% 17 51.5%
≥10.1 0 .0% 0 .0% 2
Necrosis 1 0 0% 0 0%
2 0 0% 0 0%
3 0 0% 0 0%
**Fisher’s Exact Test.
*Chi-Square Tests.could predict mortality with 81.5% sensitivity, 84.2% spe-
cificity, 96.1% positive predictive value (PPV), 48.5%
negative predictive value (NPV), 95% CI = (0.86-0.966),
AUC = 0.913, LR + = 5.163 and LR- = 0.219 (Figure 2).
Kaplan- Meier survival showed that the astrocytoma
cases with MIB-1 LI ≥ 10.1 were associated with shorter
median survival (16m ± 2.207, 95% CI: 11.674 -20.326),
when compared to those cases with MIB-1 LI < 10.1
which were associated with longer median survival
(68m ± 9.785, 95% CI: 48.822 -87.178). Therefore, there
was a high statistically significant difference between
the two groups as regards the median survival (log
rank = 54.87, P = 0.0001) (Data not tabulated) (Figure 3).
DJ-1 expression and its associations in the studied
astrocytoma cases
The DJ-1 staining pattern in the tumor cells was almost
cytoplasmic with minimal or no nuclear staining.
DJ-1 positive cytoplasmic expression was compiled in
92.8% of all cases (103/111) [score 1 (15.3%) (17/111),
score 2 (28%) (31/111), and score 3 (49.5%) (55/111)],
while the remaining 8 cases (7.2%) showed negative DJ-1
expression (score 0).
Cytoplasmic immunostaining of the tumor cells
showed a tendency to decrease in intensity with a reduc-
tion in the aggressiveness of the tumors, this was statisti-
cally evident by the high significant direct correlation
between DJ-1 staining intensity and the histological
grade (Rho = 0.815, P = 0.0001). The results disclosed
that 88.9% of the GBMs showed DJ-1 intensity (score 3),
whereas 60.7% of the diffuse astrocytoma cases exhibited
DJ-1 staining intensity (score 1) (Table 1). On further
comparison, the post hoc test (LSD) showed that there
was a high significant difference between diffuseles in the studied astrocytomas
DJ-1 2 DJ-1 3 X2 P Sig
N Row % N Row %
3 10.7% 0 .0% 113.813** .0001 HS
3 60.5% 15 39.5%
5 11.1% 40 88.9%
5 33.8% 31 41.9% 6.151* .104 NS
6 16.2% 24 64.9%
8 32.7% 20 36.4% 8.19** 0.04 HS
3 23.2% 35 62.5%
6 18.2% 2 6.1% 78.16* .0001 HS
5 32.1% 53 67.9%
2 10.5% 17 89.5% 1.186** 0.707 NS
3 16.7% 15 83.3%
0 0% 8 100%
Figure 4 DJ-1 expression in astrocytomas. a: Weak DJ-1 staining
intensity in diffuse astrocytoma (DJ-1x200). b: Moderate DJ-1
staining intensity in anaplastic astrocytoma ( DJ-1x 400). c: Strong
DJ-1 staining intensity in glioblastoma (DJ-1x200).
Abd El Atti et al. Diagnostic Pathology 2013, 8:126 Page 5 of 9
http://www.diagnosticpathology.org/content/8/1/126astrocytomas and anaplastic astrocytomas, and ana-
plastic astrocytomas and GBMs as regard DJ-1 staining
intensity (P = 0.0001) (Figure 4a, 4b and 4c).
Also a significant direct correlation was found between
DJ-1immmunoreactivity and MIB-1 LI (Rho = 0.832, P =
0.0001) and between DJ-1 and age (Rho = 0.404, P = 0.0001).
The relation between DJ-1 expression and the clinico-
pathological variables in the astrocytoma patients was
emphasized in Table 1.
In all astrocytoma cases, the univariate analysis of
overall survival showed high DJ-1 expression to be a
poor prognostic factor (Table 2) (Figure 5a). Other poor
predictors of survival on univariate analysis included old
age group (> 50), female gender, and high tumor grade
(Table 2).
On multivariate survival analysis using Cox regression,
the histopathological grade and the level of DJ-1 staining
intensity had independent prognostic significance, while
the MIB-1 LI, age and gender lost their significance
(Table 3).
When DJ-1 was analyzed as a possible prognostic factor
in each grade of the studied astrocytomas, the Kaplan-
Meier analysis proved that the anaplastic astrocytomas
showing score 3 DJ-1 were associated with shorter sur-
vival (14m), when compared to the anaplastic astrocyto-
mas with score 2 DJ-1 which were associated with longer
survival (32m) (Log rank = 17.6, P = 0.0001) (Figure 5b).
On the other hand the GBMs exhibiting score 3 DJ-1 were
associated with shorter survival (12m) than those with
score 2 DJ-1 (24m) (Log rank = 9.5, P = 0.002) (Figure 5c).
Nevertheless, in diffuse astrocytomas, DJ-1 was not
proved to significantly affect the overall survival (Log
Rank = 3.316, P = 0.191).
Multivariate survival analysis was also performed to
study the effect of the different factors including age,
gender, DJ-1, MIB-1 LI and necrosis (in GBMs only) on
the overall survival in each grade of astrocytomas. The
results showed that DJ-1 was the only independent prog-
nostic factor in the anaplastic astrocytomas [Cox regres-
sion, enter method, score 2 DJ-1 versus score 3 DJ-1,
HR = 0.217, 95% CI (0.098- 0.48), P = 0.0001) and in
the GBMs [Cox regression, backward method, score 2 DJ-
1 versus score 3 DJ-1, HR = 0.192, 95% CI (0.057- 0.653),
P = 0.008]. However, DJ-1 lost its independent association
with survival in diffuse astrocytomas (P = 0.197).
Discussion
The gold standard for diagnosis of astrocytic tumors is
the histological examination of abundantly sampled tis-
sue. Therefore, histopathology should be used in com-
bination with patient’s clinical history, the neurosurgical
suggestions and neuroradiologic findings to ensure the
greatest accuracy in the diagnosis of such tumors [16].
Histological grading is well accepted for evaluating theprognosis of astrocytoma patients. It is important to dif-
ferentiate between different grades of astrocytomas, be-
cause their clinical management differs. A number of
studies have shown that high histological grade (based
on increased cellularity, nuclear atypia, mitotic activity
and necrosis and/or microvascular proliferation) is
Table 2 Univariate analysis of the prognostic factors in relation to overall survival in the studied patients
Median survival (months) Log
rank
P value
Estimate Std error 95% CI
Age
<50 32.000 3.178 25.771-38.229 11.874 0.001(HS)
≥50 16.000 2.137 11.812-20.188
Gender
Male 26.000 3.441 19.256-32.744 4.591 0.032(S)
Female 17.000 4.054 9.055-24.945
Grade
II 68.000 ————— ——— 94.619 0.0001(HS)
III 29.000 2.055 24.973-33.027
IV 12.000 0.476 11.067-12.933
Necrosis**
1 15.000 4.353 6.468-23.532 2.081 0.353(NS)
2 12.000 1.034 9.973-14.027
3 11.000 0.943 9.152-12.848
DJ-1
0 66.833* 3.710 59.561-74.105 110.349 0.0001(HS)
1 60.000 ———— ————
2 32.000 1.017 30.007-33.993
3 12.000 0.409 11.199-12.801
*Mean.
**Necrosis is done for grade IV patients only.
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results also revealed that high histological grade was as-
sociated with decreased overall survival and proved its
independent prognostic significance.
However, the morphologic criteria are not always ac-
curate prognostic indicators. In some instances, the
histopathology diagnoses a certain grade of astrocytoma,
whereas other parameters such as the clinical and neu-
roimaging features indicate a more advanced grade.
Therefore, recent researches investigated the expres-
sion of novel prognostic biomarkers in astrocytic tu-
mors that could lead to an accurate classification and
effective treatment. For instance, the hypermethylation
status of the epidermal growth factor receptor (EGFR)
and methyl-guanine-DNA methyltransferase (MGMT)
could play a role in glioma progression [19]. In
addition, Gulati et al. [20] indicated the adverse prog-
nostic effect of C-erbB2 (a member of EGFR family)
overexpression in anaplastic astrocytomas. Other relevant
markers are the proliferation markers as minichromosome
maintenance protein2 (Mcm2), survivin, mitosin and
Ki67/MIB-1 [21,22].
MIB-1 LI is one of the cell proliferation markers that
had been extensively employed by the histopathologists
in conjunction with the traditional morphologic vari-
ables. It supports better determination of the histologicalgrade and consequently the prognosis of astrocytoma
patients [23,24].
Most of the studies have found significant differences
in MIB-1 labeling indices between low and high grade
astrocytomas [5,25,26]. In support to the previous stud-
ies, our results showed a significant direct correlation
between MIB-1 LI and the histological grade. A signifi-
cant difference was detected between the diffuse and the
anaplastic astrocytomas, and the anaplastic astrocytomas
and GBMs. However, Hsu et al. [25] and Rodriguez-
Pereira et al. [27] could not find a significant difference
between the anaplastic astrocytomas and GBMs as
regards MIB-1 LI.
The majority of the previous studies proposed several
prognostic MIB-1 cut off values that ranged from 1.5%
to 15.3% [4,28-30]. This wide range makes the interpret-
ation and comparisons between the different results dif-
ficult. Nevertheless, a MIB-1 LI greater than 10 may
serve as a commonly used value to express a more ag-
gressive phenotype of astrocytomas.
The results of our study succeeded in identifying a
MIB-1 cut off value of 10.1 for distinguishing astrocyto-
mas with good prognosis from cases with poor prognosis.
The univariate analysis revealed a significant reduction in
the overall survival of astrocytoma patients with MIB-1 LI
≥10.1. However this significant association with survival
Figure 5 Kaplan-Meier overall survival curves according to DJ-1
level. a: In all astrocytoma cases. b: In anaplastic astrocytoma cases.
c: In glioblastoma cases.
Table 3 Multivariate cox regression model of overall
survival among all cases
HR P Sig. 95.0% CI for HR
Age 1.011 .355 NS .988 1.034
Female 1.202 .419 NS .769 1.879
Grade* .005 HS
Grade II .220 .551 NS .084 3.745
Grade III .320 .001 HS .196 .679
MIB >10.1 2.661 .077 NS .899 7.870
DJ 1** .0001 HS
DJ1(1) 2.561 .230 NS .551 11.895
DJ1(2) 5.396 .093 NS .754 38.621
DJ1(3) 28.978 .002 HS 3.618 232.094
*Grade IV reference.
**DJ0 reference.
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possible prognostic factors as age, gender, histological
grade and DJ-1 protein expression.
Though some studies claimed that MIB-1 LI is an in-
dependent prognostic variable [5,31-33], others found it
significant only in univariate analysis in concordance
with our results [4,27,34].
The present study shows that MIB-1 LI could not also
provide an independent role for predicting survival when
Cox regression analysis was carried out for each grade of
astrocytoma. This finding agreed with the results of
McKeever et al. [35], Korshunov et al. [36] and
Moskowitz et al. [37] which could not establish any
prognostic role for MIB-1 LI on Cox regression analysis
in diffuse, anaplastic astrocytoma and GBMs respectively.
On the other hand, Giannini et al. [5] and Hsu et al. [25]
found that MIB-1 LI was an independent prognostic indi-
cator in the diffuse and anaplastic astrocytomas. Also
Wakimoto et al. [33] confirmed the independent adverse
effect of MIB-1 LI on survival in high-grade astrocytomas
only.
There are many factors responsible for such a variation
in MIB-1 labeling indices in many studies. The variabil-
ity in tissue processing, immunohistochemical proce-
dures and the different quantitation methods, make it
difficult to determine a certain cut off value for clinical
use. Also, the degree of inter-observer variability affects
the clinical usefulness of such cut off values.
In the view of seeking additional prognostic markers
in different grades of astrocytomas and owing to the well
established anti-apoptotic and cell survival function of
DJ-1 protein, we studied the applicability of using DJ-1
as a survival predictor marker in the studied cases of
astrocytomas.
Similar to our study, Junn et al. [38] demonstrated that
DJ-1 is present mostly in the cytoplasm of the tumor
cells and to a lesser extent in the nucleus. They reported
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and mitochondria, and that mitochondrial DJ-1 appears
to be primarily responsible for protection against oxida-
tive stress.
The current results revealed a strong positive correl-
ation between the cytoplasmic staining intensity of DJ-1
and the histological grade of astrocytomas.
Hinkle et al. [39] was the first to show that DJ-1 cyto-
plasmic immunoreactivity was strong in GBMs, while
Miyajima et al. [40] conducted the leading study which
confirmed that DJ-1 is localized in the cytoplasm in
addition to the nucleus of tumor cells of astrocytomas
and that the nuclear DJ-1 was inversely correlated with
WHO grading.
In addition to the direct correlation between DJ-1 and
grading, our results also demonstrated a strong associ-
ation between DJ-1 and MIB-1 LI in the studied cases of
astrocytomas. This supports the role of DJ-1 in neoplas-
tic transformation and tumor proliferation, which is evi-
dent in several human cancers. This also reveals the
molecular mechanisms by which DJ-1 is involved in can-
cer cell survival and aggressiveness of tumors [41].
In our set of 111 astrocytoma cases, increased cyto-
plasmic staining intensity of DJ-1 was associated with
shortened overall survival upon univariate analysis. Fur-
thermore, high DJ-1 expression was the only independent
prognostic factor affecting survival in combination with
histological grade. This was contradicted by Miyajima
et al. [40] who concluded that reduced nuclear DJ-1 ex-
pression was associated with shorter survival, whereas
there was no correlation between the level of DJ-1 cyto-
plasmic expression and the prognosis of their cohort of
astrocytoma patients. This controversy may result from
the variation in the subcellular localization of DJ-1 and
consequently DJ-1 might have different functions in the
different cellular compartments.
When the astrocytoma cases were stratified according
to WHO grading system, a significant association be-
tween DJ-1 staining intensity and the patient’s overall
survival was observed in high-grade astrocytomas (ana-
plastic astrocytomas and GBMs). In anaplastic astrocyto-
mas, strong DJ-1 staining (score 3) was able to identify
patients with shorter survival than those exhibiting mod-
erate DJ-1 staining (score 2). Also the variation in DJ-1
staining intensity stratified the GBM patients into a
group with better survival (score 2 DJ-1) and a group
with worse survival (score 3 DJ-1). However, DJ-1 was
not significantly associated with survival in the cohort of
diffuse astrocytoma patients.
The differential expression of DJ-1 particularly in ana-
plastic astrocytomas may have a future significance in
identifying subclasses that are more aggressive or more
likely associated with worse prognosis. This could be par-
ticularly important in cases where histopathology revealslower grades of astrocytoma, while other factors indicate
more malignant phenotypes. The effect on patient’s overall
survival in high grade astrocytomas was restricted to DJ-1
rendering it a poor prognostic indicator independent of
other factors including MIB-1 LI.
Therefore, this study emphasizes the adverse prognos-
tic role of high DJ-1 expression in astrocytoma patients.
It was the first, to the best of our knowledge, to set up a
statistical survival analysis in which DJ-1 has a more
valuable role in predicting survival when compared to
MIB-1 especially in high grade astrocytomas.
MIB-1 is an important clinical marker in astrocytomas.
Nevertheless, several shortcomings make it difficult to
standardize a proliferation index for prognostic pur-
poses. Therefore future studies, on a larger scale, are
recommended in a trial to apply DJ-1 protein as a pos-
sible adjunct or even an alternative to MIB-1 immuno-
histochemistry especially in the histological borderline
cases such as those at the grade II-III border and grade
III-IV border.
In conclusion, though the histological grade still ap-
pears to be the best guideline to prognosis in astrocy-
toma patients, in many instances, there is dissociation
between the morphologic criteria and clinical parame-
ters. Therefore, immunohistochemical procedures using
DJ-1 might serve as a very useful supporting tool to the
histopathological diagnosis.Consent
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